Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30948747 | 0.94 | PTPN1 (0.48) | PTPN1CTSSCTSKGRB2MDM4 | |
| SCHEMBL30948706 | 0.93 | PTPN1 (0.52) | PTPN1CTSKGRB2MDM4TP53 | |
| SCHEMBL30948792 | 0.92 | PTPN1 (0.47) | PTPN1CTSSCTSKGRB2SCN9A | |
| SCHEMBL30919303 | 0.91 | PTPN1 (0.44) | PTPN1MDM4TP53 | |
| SCHEMBL30948674 | 0.89 | MDM4 (0.45) | MDM4TP53 | |
| SCHEMBL30948700 | 0.87 | CTSL (0.46) | PTPN1SCN9A | |
| SCHEMBL30919280 | 0.87 | PTPN1 (0.44) | PTPN1MDM4TP53 | |
| SCHEMBL30948717 | 0.87 | MDM4 (0.41) | PTPN1MDM4TP53 | |
| SCHEMBL30948714 | 0.87 | PTPN1 (0.45) | PTPN1CTSSCTSKSCN9AMDM4 | |
| SCHEMBL30948814 | 0.87 | PTPN1 (0.48) | PTPN1GRB2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | PTPN1 2023/4885CTSS 1400/4885CTSK 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.